U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent
In the inter partes review (IPR) proceedings initiated by
"We are pleased with today's ruling by the U.S. PTO finding the claims of the Alimta vitamin regimen patent are valid," said
Harrington continued, "The significant scientific research that Lilly performed in support of the vitamin regimen patent deserves intellectual property protection, which has been confirmed in every validity challenge to date. We continue to emphasize that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. These rights help support the development of the next generation of innovative medicines."
In
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. C-LLY
This release contains forward-looking statements regarding the U.S. Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially. There can be no assurance that the company will prevail in any appeal. Also, the company cannot predict whether generic pemetrexed will be marketed prior to the expiration of the vitamin regimen patent. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the
Alimta® (pemetrexed, Lilly)
Refer to: |
Lauren Zierke; lauren_zierke@lilly.com; (317) 989-2853 (Media) |
Phil Johnson; johnson_philip_l@lilly.com; (317) 655-6874 (Investors) |
View original content with multimedia:http://www.prnewswire.com/news-releases/us-patent-and-trademark-office-rules-in-lillys-favor-on-alimta-vitamin-regimen-patent-300532094.html
SOURCE